Table 1.
The vaccine effectiveness (VE) of various types of vaccines on different mutants.
| BA.5 | BF.7 | XBB | XBB.1 | XBB.1.5 | BQ.1 | BQ.1.1 | XBB.1.16 | |
|---|---|---|---|---|---|---|---|---|
| Recombinant Protein Vaccines | ||||||||
| Three doses of vaccine (ZF2001*3) |
-7.19 times (pVNT50, PT, pVNT, 1302 vs. 181) (43) |
-20.7times (pVNT50, PT, pVNT, 1302 vs. 63) (43) |
-217 times (pVNT50, PT, pVNT, 1302 vs. 6) (43) |
-144times (pVNT50, PT, pVNT, 1302 vs. 9) (43) |
-217times (pVNT50, PT, pVNT, 1302 vs. 6) (43) |
|||
| Three doses of vaccine (Recombinant Protein Vaccines *2 +ZF2001 *1) | -30.07 times (pVNT50, PT, pVNT, 812 vs. 27) (43) |
-36.90 times (pVNT50, PT, pVNT, 812 vs. 22) (43) |
-135.33 times (pVNT50, PT, pVNT, 812 vs. 6) (43) |
-135.33times (pVNT50, PT, pVNT, 812 vs. 6) (43) |
-135.33times (pVNT50, PT, pVNT, 812 vs. 6) (43) |
|||
| Inactivated Vaccines | ||||||||
| Three doses of vaccine (Inactivated Vaccines*3) | -5.0 times (pVNT50, PT, pVNT, 131 vs. 26) (43) |
-13.1times (pVNT50, PT, pVNT, 131 vs. 10)[1] |
-26.2times (pVNT50, PT, pVNT, 131 vs. 5) (43) |
-14.56times (pVNT50, PT, pVNT, 131 vs. 9) (43) |
-21.83times (pVNT50, PT, pVNT, 13 1vs. 6) (43) |
|||
| Three doses of vaccine (CoronaVac [Sinovac] or BBIBP-CorV [Sinopharm])*3 |
-2.04times (NT50, G614, pVNT, 1-5month, 47 vs. 23) (63) |
-3.13times (pVNT50, G614, NT, 1-5month 47 vs. 15) (63) |
-7.83times (pVNT50, G614, NT, 1-5month, 47 vs. 6) (63) |
-5.88times (pVNT50, G614, NT, 1-5month, 47 vs. 8) (63) |
||||
| Three doses of vaccine (CoronaVac*)3 | -3.03 times (pVNT50, WT, pVNT, 97 vs. 32) (9) |
-3.23 times (pVNT50, WT, pVNT, 97 vs. 30) (9) |
-3.23 times (pVNT50, WT, pVNT, 97 vs. 30) (9) |
-29times (ID50, D614G, pVNT, 14d, 516 vs. 18) (64) |
-3.23 times (pVNT50, WT, pVNT, 97 vs. 30) (9) |
-3.23 times (pVNT50, WT, pVNT, 97 vs. 30) (9) |
-3.23 times (pVNT50, WT, pVNT, 97 vs. 30) (9) |
|
| -16times (ID50, D614G, pVNT, 14d, 516 vs. 32) (64) |
-15times (ID50, D614G, pVNT, 14d, 516 vs. 35) (64) |
-40imes (ID50, D614G, pVNT, 14d, 516 vs. 13) (64) |
-29times (ID50, D614G, pVNT, 14d, 516 vs. 18) (64) |
-27times (ID50, D614G, pVNT, 14d, 516 vs. 19) (64) |
||||
| mRNA Vaccines | ||||||||
| Three doses of vaccine (BNT162b2 *3) | -9.45 times (pVNT50, WT, pVNT, 2014 vs. 213) (9) -11.44times(ID50, WA1, pVNT, 2882 vs. 252) (68) |
-24.7 times(pVNT50, WT, pVNT, 2014 vs. 83) (9) | -62.94 times (pVNT50, WT, pVNT, 2014 vs. 32) (9) |
-435.19times (WA1/2020, pVNT, 2021, 45695 vs. 105) (67) |
-57.54 times (pVNT50, WT, pVNT, 2014 vs. 35) (9) |
-38.73 times (pVNT50, WT, pVNT, 2014 vs. 52) (9) |
-44.75 times (pVNT50, WT, pVNT, 2014 vs. 45) (9) -39.48times (ID50, WA1, pVNT, 2882 vs. 73) (68) |
|
| -51.52times (WA1/2020, pVNT, 2021, 45695 vs. 887) (67) |
-76.80times (WA1/2020, pVNT, 2021, 4569 5 vs. 59) (67) |
-80.10times (ID50, WA1, pVNT, 2882 vs. 36) (68) |
-90.06times (ID50, WA1, pVNT, 2882 vs. 32) (68) |
-175.08times (WA1/2020, pVNT, 2021, 45695 vs. 261) (67) |
||||
| Two doses of vaccine (Monovalent mRNA Vaccines*2) |
83%(14-150days, during BA.4/BA.5 period) (65) 37%(≥150days, duringBA.4/BA.5 period) (65) |
|||||||
| Three doses of vaccine (Monovalent mRNAVaccines*3) | -12times (ID50, D614G, pVNT, 7687 vs. 628) (14) |
<-70times (ID50, D614G, pVNT, 7687 vs. <111) (14) |
<-71times (ID50, D614G, pVNT, 7687 vs. <108) (14) -50.36times(pVNT50, G614, pVNT, 1-5month, 1662 vs. 33) (63) |
<-37times (ID50, D614G, pVNT, 7687 vs. <208) (14) |
<-55times (ID50, D614G, pVNT, 7687 vs. <139) (14) |
|||
| 60%(7-120days, duringBA.4/BA.5 period) (65) 29%(≥120days, duringBA.4/BA.5 period) (65) |
||||||||
| +1.61times (pVNT50, BA.1, pVNT, 1686 vs. 1049, for men) (80) |
||||||||
| -3.11times (pVNT50, G614, pVNT, 1-5month, 1662 vs. 535) (63) |
-5.91times (pVNT50, G614, pVNT, 1-5month, 1662 vs. 281) (63) |
-17.68times (pVNT50, G614, pVNT, 1-5month, 1662 vs. 94) (63) |
||||||
| -12.66times (FRNT50, UT-NC002-1T, FRNT, 180-189days, 257 vs. 20.3) (66) |
-21.60 times (FRNT50, UT-NC002-1T, FRNT, 180-189days, 257 vs. 11.9) (66) |
-21.07times (FRNT50, UT-NC002-1T, FRNT, 180-189days, 257 vs. 12.2) (66) |
||||||
| Four doses of vaccine (Monovalent mRNAVaccines*4) |
-16.14times (FFRNT50, USA-WA1/2022, FFRNT, 23-94days, 1533 vs. 95) (69) |
-22.22times (FFRNT50, USA-WA1/2022, FFRNT, 23-94days, 1533 vs. 69) (69) |
<-145times (ID50, D64G, pVNT, 21182 vs. <147) (14) |
-102.2times (FFRNT50, USA-WA1/2022, FFRNT, 23-94days, 1533 vs. 15) (69) |
<-43times (ID50, D64G, pVNT, 21182 vs. <496) (69) |
-69.68times (FFRNT50, USA-WA1/2022, FFRNT, 23-94days, 1533 vs. 22) (69) |
||
| 61%(7-120days, duringBA.4/BA.5 period) (65) | ||||||||
| -11.69times (FRNT50, UT-NC002-1T, FRNT, 33-57days, 727 vs. 62.2) (66) |
-108.30times (FRNT40, UT-NC002-1T, FRNT, 1527 vs. 14.1) (11) |
-114.81times (FRNT40, UT-NC002-1T, FRNT, 1527 vs. 13.3) (11) |
-43.27times (FRNT50, UT-NC002-1T, FRNT, 33-57days, 727 vs. 16.8) (66) |
|||||
| -14times (ID50, D64G, pVNT, 21182 vs. <1540) (14) |
-51.56times (FRNT50, UT-NC002-1T, FRNT, 33-57days, 727 vs. 14.1) (66) |
<-155times (ID50, D64G, pVNT, 21182 vs. <137) (14) |
<-81times (ID50, D64G, pVNT, 21182 vs. <261) (14) |
|||||
| Four doses of vaccine (BNT162b2 *3+Bivalent vaccine Booster *1) |
-4.32times (FRNT50, USA-WA1/2020, Participants without SARS-CoV-2 Infection before Dose 4, 2237 vs. 518) (70) |
-56.75times (ID50, WA1, pVNT, 11009 vs. 194) (68) |
-40.67times (FRNT50, USA-WA1/2020, Participants without SARS-CoV-2 Infection before Dose 4, 2237 vs. 55) (70) |
-54.23times (ID50, WA1, pVNT, 11009 vs. 203) (68) |
-15.64times (FRNT50, USA-WA1/2020, Participants without SARS-CoV-2 Infection before Dose 4, 2237 vs. 143) (70) |
|||
| -3.52times (FRNT50, USA-WA1/2020, Participants with SARS-CoV-2 Infection before Dose 4, 4847 vs. 1377) (70) |
-37times (FRNT50, USA-WA1/2020, Participants with SARS-CoV-2 Infection before Dose 4, 4847 vs. 131) (70) |
-10.92times (FRNT50, USA-WA1/2020, Participants with SARS-CoV-2 Infection before Dose 4, 4847 vs. 444) (70) |
||||||
| -4.35times (ID50, WA1, pVNT, 11009 vs. 2533) (68) |
-27.52times (ID50, WA1, pVNT, 11009 vs. 400) (68) |
|||||||
| Four doses of vaccine (BNT162b2 *3+Monovalent vaccine Booster *1) |
-14.89times (FRNT50, USA-WA1/2020, Participants without SARS-CoV-2 Infection before Dose 4, 1325 vs. 89) (70) |
-77.94times (FRNT50, USA-WA1/2020, Participants without SARS-CoV-2 Infection before Dose 4, 1325 vs. 17) (70) |
-53times (FRNT50, USA-WA1/2020, Participants without SARS-CoV-2 Infection before Dose 4, 1325 vs. 25) (70) |
|||||
| -8.14times (FRNT50, USA-WA1/2020, Participants with SARS-CoV-2 Infection before Dose 4, 5120 vs. 629) (70) |
-52.24times (FRNT50, USA-WA1/2020, Participants with SARS-CoV-2 Infection before Dose 4, 5120 vs. 98) (70) |
-38.79times (FRNT50, USA-WA1/2020, Participants with SARS-CoV-2 Infection before Dose 4, 5120 vs. 132) (70) |
||||||
| Four doses of vaccine (monovalent BNT162b2/Comirnaty vaccine booster)*1 | -151.33 times (PVNT50, B.1, PVNT, 454 vs. 3) (75) |
-113.50 times (PVNT50, B.1, PVNT, 454 vs. 4) (75) |
||||||
| Four doses of vaccine (bivalent BNT162b2/Comirnaty Original/Omicron BA.4-5 vaccine booster)*1 | -44.27 times (PVNT50, B.1, PVNT, 974 vs. 22) (75) |
-57.29times (PVNT50, B.1, PVNT, 974 vs. 17) (75) |
||||||
| Monovalent mRNA Booster*1 (most of whom had received three previous doses of vaccine.) |
-7.60times (WA1/2020, pVNT, 2022, 21507 vs. 2276) (67) |
-9.45times (WA1/2020, pVNT, 2022, 21507 vs. 2829) (67) |
-126.51times (WA1/2020, pVNT, 2022, 21507 vs. 170) (67) |
-52.97times (WA1/2020, pVNT, 2022, 21507 vs. 406) (67) |
||||
| Bivalent mRNA Booster*1 (most of whom had received three previous doses of vaccine.) |
-10.97times (WA1/2020, pVNT, 2022, 40515 vs. 3693) (67) |
-16.89times (WA1/2020, pVNT, 2022, 40515 vs. 2399) (67) |
-231.51times (WA1/2020, pVNT, 2022, 40515 vs. 175) (67) |
-79.75times (WA1/2020, pVNT, 2022, 40515 vs. 508) (67) |
||||
| Monovalent mRNA Booster*1 | -17.14times (FRNT50, WA1/2020, FRNT, 857 vs. 50) (21) |
-45.11times (FRNT50, WA1/2020, FRNT, 857 vs. 19) (21) |
||||||
| Monovalent mRNA Booster*2 | -9.41times (FRNT50, WA1/2020, FRNT, 2352 vs. 250)21 |
-63.57times (FRNT50, WA1/2020, FRNT, 2352 vs. 63.6) (21) |
-32.22times (FRNT50, WA1/2020, FRNT, 2352 vs. 32.2) (21) |
|||||
| Bivalent mRNA Booster*1 | -4.31times (FRNT50, WA1/2020, FRNT, 2481 vs. 576) (21) |
-25.84times (FRNT50, WA1/2020, FRNT, 2482 vs. 96) (21) |
-22.15times (FRNT50, WA1/2020, FRNT, 2482 vs. 112) (21) |
|||||
| Four doses of vaccine (bivalent (WT and BA.5) COVID-19 mRNA vaccines booster)*1 | <-8.1times (ID50, D614G, pVNT, 13736 vs. 1688) (14) |
<-66times (ID50, D614G, pVNT, 13736 vs. <209) (14) |
<-85times (ID50, D614G, pVNT, 13736 vs. <162) (14) |
<-24times (ID50, D614G, pVNT, 13736 vs. <568) (14) |
<-41times (ID50, D614G, pVNT, 13736 vs. <337) (14) |
|||
| Five doses of vaccine (monovalent mRNA : BNT162b2 Or mRNA1273)*4+ (Bivalent(ancestral+BA.4/5)mRNA vaccine)*1 |
-36.57imes (FRNT40, UT-NC002-1T, FRNT, 1086 vs. 29.7) (11) |
-33.62times (FRNT40, UT-NC002-1T, FRNT, 1086 vs. 32.2) (11) |
||||||
| BA.5 bivalent booster*1 (Monovalent mRNA *two or three or four before booster) |
-12.15times (FFRNT50, USA-WA1/2022, FFRNT, 23-94days, without infection history, 3620 vs. 298) (69) |
-11.87times (FFRNT50, USA-WA1/2022, FFRNT, 23-94days, without infection history, 3620 vs. 305) (69) |
-103.42times (FFRNT50, USA-WA1/2022, FFRNT, 23-94days, without infection history, 3620 vs. 35) (69) |
-49.59times (FFRNT50, USA-WA1/2022, FFRNT, 23-94days, without infection history, 3620 vs. 73) (69) |
||||
| -3.71times (FFRNT50, USA-WA1/2022, FFRNT, 23-94days, with infection history, 5776 vs. 1558) (69) |
-4.72times (FFRNT50, USA-WA1/2022, FFRNT, 23-94days, with infection history, 5776 vs. 1223) (69) |
-56.08times (FFRNT50, USA-WA1/2022, FFRNT, 23-94days, with infection history, 5776 vs. 103) (69) |
-21.63times (FFRNT50, USA-WA1/2022, FFRNT, 23-94days, with infection history, 5776 vs. 267) (69) |
|||||
| Two, three or four doses of vaccine (monovalent mRNA : BNT162b2 or mRNA-1273 or NA vaccines)*two or three or four +BA.2 breakthrough |
-4.80times (NT50, B.1.1, pVNT, 1918 vs. 400) (12) |
-15.98times (NT50, B.1.1, pVNT, 1918 vs. 120) (12) |
-15.22times (NT50, B.1.1, pVNT, 1918 vs. 126) (12) |
-13.50times (NT50, B.1.1, pVNT, 1918 vs. 142) (12) |
||||
| Two, three or four doses of vaccine (monovalent mRNA : BNT162b2 or mRNA-1273 or NA vaccines) *two or three or four +BA.5breakthrought |
-2.51times (NT50, B.1.1, pVNT, 6900 vs. 2741) (12) |
-30.67times (NT50, B.1.1, pVNT, 6900 vs. 225) (12) |
-37.10times (NT50, B.1.1, pVNT, 6900 vs. 186) (12) |
-27.38times (NT50, B.1.1, pVNT, 6900 vs. 252) (12) |
*One dose: The vaccine was immunized once. Two doses: the vaccine was immunized twice. Three doses: the vaccine was immunized thrice. Four doses: the vaccine was immunized four times. Booster dose, vaccines added to strengthen immunity. IC50, 50% true virus neutralization titer; ID50, Infection dose 50. pVNT50, 50% pseudovirus neutralization titer. PRNT50, 50% plaque reduction neutralization test. D614G, taking the D614 G mutant as the reference object. WT, taking the wild-type (Wuhan-hu-1), SARS-CoV-2 prototype (PT), UT-NC002-1T, and B.1.1 as the reference. The new variant strain’s GMT compared with the comparative strain’s GMT, with a ratio greater than 0 and a positive multiple. Greater than 0 times (green), 0–10 times (yellow), -10–50 times (blue), -50–100 times (purple), greater than -100 times (red), vaccine effectiveness (orange). 1–5 month: 1–5 months after administration, 33–57 days: 33–57 days after administration, 23–94: 23–94 days after administration.